Unexpected papilledema in a young male with Type 1 diabetes

Juan A. Paniagua1,2, Rodrigo Bahamondes1, Antonio Cano-Sánchez2,3 & Francisco Velasco2,4

1Physician of Endocrinology and Nutrition Service, University Hospital Reina Sofia (UHRS), Córdoba, Spain
2Maimonides Institute of Biomedical Research (IMIBIC), Córdoba, Spain
3Physician of Radiology Service, UHRS, IMIBIC, Córdoba, Spain
4Physician of Hematology Service, UHRS, IMIBIC, Cordoba, Spain

Correspondence
Juan A. Paniagua, Endocrinology and Nutrition Service, University Hospital Reina Sofia (UHRS), Avda Menéndez Pidal, s/n. 14004, Córdoba, Spain. Tel: 34-957011235; Fax: +34-957011235; E-mail: japaniaguag@yahoo.es

Funding information
Supported by grants: To JA Paniagua from secretaría General de Calidad y Eficiencia, Junta de Andalucía (0462/2006; AI-0027/2029/2010). Grupos PAI. Junta de Andalucía. CTS651. 2009-2012

Received: 24 April 2016; Revised: 21 May 2017; Accepted: 30 May 2017

Clinical Case Reports 2017; 5(8): 1333–1338
doi: 10.1002/ccr3.1067

Introduction

In young people with type 1 diabetes (T1D), the most common cause of acute neurological deterioration is cerebral edema. Therefore, intracerebral vascular thrombosis, subarachnoid hemorrhage, meningoencephalitis, and ischemic stroke should also be considered, all of which are often associated with an episode of acute diabetic ketoacidosis (DKA) in patients with T1D.

Papilledema (or papilloedema) is optic disk swelling, and detection of bilateral papilledema is related with causes that increase intracranial pressure (Table S1). Thus, an evaluation with a computed tomography (CT) and magnetic resonance images (MRI) studies of the brain should be quickly performed. In general population, the incidence of cerebral venous thrombosis is approximately three to four cases per million affecting mainly patients <40 years old. It is three times more prevalent in women mostly during pregnancy or taking hormonal contraceptive drugs, and special attention should be given to identifying carriers of inherited thrombophilia. However, cerebral venous sinus thrombosis (CVST) is an uncommon form of presentation of stroke affecting young patients [1]. Therefore, in a study performed in children and young adults (<18 years old), an incidence of CVST of 6.7 per million per year was reported [2]. In addition, in a meta-analysis, it was observed that only two of 149 children with CVST were found to have diabetes without acute hyperglycemia or DKA [3]. Finally, the largest study of CVST, the international Study on Cerebral Vein and Dural Sinus Thrombosis, included 624 patients in a prospective observational, multicenter and multinational study, found an inherited prothrombotic condition in 22% of patients [4]. Here, we report a case of asymptomatic presentation of a CVST in a youth with T1D identified after detection of a bilateral papilledema in a routine outpatient retinography.

Key Clinical Message

In young patients with T1D, neurological manifestations of cerebral hypertension should suggest the possibility of a cerebral venous sinus thrombosis (CVST). In these patients an inherited prothrombotic risk factor, including factor V Leiden G1691A gene mutation, should be considered during an event of thrombosis. Improving the glycemic control is the first factor that should be controlled in a patient who carries a genetic prothrombotic risk factor. Anticoagulant treatment should be started as soon as CVST has been diagnosed. Long-term antithrombotic treatment with tinzaparin 175 IU/kg/day, a low-molecular weight heparin (LMWH), could be reliable and well tolerated, although an indefinite special follow-up, including neurological controls, is advisable even in asymptomatic patients.

Keywords

Cerebral venous sinus thrombosis, inherited thrombophilia, low-molecular weight heparin treatment, papilledema, type 1 diabetes.
Case History and Examination

A 15-year-old boy with T1D since the age of nine was presented on a routine visit with a fasting glucose of 12.43 mmol/L and HbA1c of 76 mmol/mol, serum total cholesterol of 3.37 mmol/L, and thyroid-stimulating hormone of 3.66 mUI/L. He was asymptomatic and his physical examination showed a weight of 79-kg with a height of 174-cm and blood pressure (BP) of 139/78 mmHg with a heart rate of 93 bpm. He was afebrile, and his head and neck, abdomen, and extremities were also normal. Others results from urinalysis (including microalbuminuria and ketones), complete blood cell counts, and liver and kidney functions were all normal. A year before, the retinal exploration was normal (ophthalmology report). Insulin treatment was glargine 38 units at bedtime plus aspart before each meal (≈11, 12 and 11 Units; total insulin 0.91 Units/kg/day). Four weeks before, he presented an acute gastroenteritis accompanied by an intermittent frontal headache without showing any warning signs (neurological, ophthalmological, etc.). The headache did not stop his normal routine including school activities. He was treated with minor analgesics (paracetamol) and progressively improved over a 2 week period. It was interpreted as minor in relation to a likely acute viral gastroenteritis. The patient was encouraged to reinforce diabetes education, and a new retinography was requested, when a bilateral papilledema was unexpectedly diagnosed (Fig. 1, panel A left and right). Immediately, the patient was sent to the emergency department where a CT and MRI studies without contrast were unremarkable (Figure S1). Subsequently, sagittal and axial reformatted images from the contrast-enhanced magnetic resonance venography (MRV) showed, in both the superior sagittal sinus and the right transverse sinus, the presence of filling defects compatible with sinus thrombosis (Fig. 2, panel C and D, arrows).

Differential diagnosis

The clinical presentation of an episode of cerebral thrombosis may be mainly due to two pathophysiological mechanisms in the brain. Therefore, the CVST quickly increases the pressure in veins and brain capillaries. In addition, the thrombosis “per se” has inflammatory actions that generate a perivascular cerebral edema, which again increases capillary pressure and in conjunction with the inflammation on the vessels increases the likelihood of cerebral hemorrhage. Thus, a wide clinical variability can be observed in the presentation of a CVST.

Figure 1. Retinography showing an unexpectedly diagnosed bilateral papilledema (panel A, left and right). A new retinography demonstrated a dramatic improvement of papilledema after 6 months (panel B, left and right).
Symptoms may be mostly derived from those produced by intracranial hypertension (p.e. papilledema) and others resulting from a focal neurological deficit. Finally, the clinical course may be acute, subacute and more latent, or chronic, considering the time evolution. Four main syndromes can be observed such as isolated intracranial hypertension syndrome (90%), focal neurological abnormalities (44%), seizures (30–40%), and encephalopathy which are more likely in elderly patients.

In the case described here, a bilateral papilledema was suddenly observed in a young boy with T1D in a routine outpatient visit. The patient was asymptomatic, although his metabolic control was bad (HbA1c~10%); however, he was stable without glycemic variability. Quickly, neurological explorations were made including the result of a lumbar puncture, and no findings resulted. In addition, ophthalmological examination was found to be normal, and a careful evaluation of retinography images noted that no diabetic retinopathy lesions were present. The patient’s medical history revealed that only an episode of headache without symptoms of neurological deficiency was noted, associated with an episode of gastroenteritis. This was treated with minor analgesics and did not stop his daily life and had gradually improved at to the date of the consultation. Headache may be present in up to 90% of patients with CVST and can be generalized or focused and often increases with Valsalva maneuver or exercise [5]. Initially, on the day of the consultation, CT and MRI studies without contrast showed no orbital or brain lesions. However, after a MRV the presence of thrombus both in the superior sagittal sinus and the transverse sinus was observed. Therefore, while MRI may give a good signal of deep veins or sinuses on T1-weighted images and in brain tissue near to venous thrombosis, MRV provides the best evaluation of partially clogged sinuses, as in this case.

One or more risk factors can usually be identified in over 85% of patients with CVST (Table S2) [4, 6]. Risk factors for thrombosis are usually divided into inherited (thrombophilia) and acquired. At evaluation, a complete investigation of primary hypercoagulability by inherited risk factors was carried out. Levels of antithrombin III and protein S and C were normal. American Heart Association defines as high-risk thrombophilias homozygosis for either factor V Leiden or G20210A mutations [7]. However, whereas the mutation G20210A of prothrombin gene was absent, a state of thrombophilia was diagnosed because the patient was a heterozygous carrier of the factor V Leiden G1691A mutation.

In addition, acquired precipitating factors are frequently found in patients with thrombosis, increasing the risk of genetic prothrombotic states. Therefore, a thorough investigation of clinical and analytical data of acquired prothrombosis risk factors was made. In developed countries, the more common of these include oral contraceptives (~22-fold risk of CVT), pregnancy and puerperium, but this was not applicable to this patient [4]. The presence of “antiphospholipid antibodies” such as anti-β2-glycoprotein I, anticardioliopin antibodies, and lupus anticoagulant was negative, and homocysteinemia level was normal. Other frequent factors including head trauma, cancer, exogenous hormones and drugs, localized and systemic infections [including parameningeal locations], hematologic disorders, chronic inflammatory diseases, and neurosurgical procedures were discarded. Therefore, of relevance in this patient, a probably viral infection, bad control of T1D, and a heterozygous carrier of the factor V Leiden were identified. This mutation is quite frequent in Caucasians and can be found in 5% of the general population of European descendents, but increases up to 11–21% in patients with venous thromboembolism [8]. Thus, subjects with the factor V Leiden G1691A mutation have a risk of deep vein thrombosis seven times higher than subjects without the mutation. Coagulation disorders have been reported in 39 of 123 (32%) children with CVST, while an inherited

Figure 2. Filling defects in both superior sagittal sinus and right transverse sinus, findings consistent with thrombosis are shown (panel C and D, arrows).
hyperglycemia on admission is a strong predictor for poor clinical outcome in patients with CVT, even without a previous history of diabetes mellitus [15]. However, whether tight glucose control can improve, the outcome of these patients needs to be observed in a specific randomized clinical trial.

**Treatment**

Treatment with anticoagulants may reduce thrombus propagation, appearance of other venous infarcts, and neurological impairment in patients with CVST. Thus, anticoagulant treatment should be started as soon as CVST has been diagnosed. Initial anticoagulation is advised with adjusted-dose unfractionated heparin or weight-based low-molecular weight heparin, regardless of the possible presence of intracerebral hemorrhagic lesions [7, 16, 17]. As necessary, management of seizures, severe headache, and increased intracranial pressure may require a neurological and neurosurgical approach. In this patient, tinzaparin 175 UI/kg/day was started, and 6 months later a new retinography demonstrated a dramatic improvement of papilledema (Fig. 1, panel B left and right). However, at this time in the control with MRV the persistence of thrombus in the transverse sinus was observed, although fewer in number and smaller in size. Therefore, treatment with tinzaparin was subsequently extended for another 6 months (12 months). The young man remained asymptomatic during all this time.

In addition, the suboptimal metabolic control at the time of diagnosis (10% HbA1c) was improved after appropriate intensification of lifestyle in our nursing clinic, and by adjusting his bolus-basal insulin pattern to prandial capillary plasma glucose between 80 and 130 mg/dL, and postprandial capillary plasma glucose <180 mg/dL, and after 3 months treatment the HBA1c was 7.2%, very close to the 7% control goal set by the standards of medical care in diabetes of the American Diabetes Association (ADA) [18].

**Patient’s perspective**

In a meta-analysis that grouped 1180 patients with CVT, the mortality rate at 30-days was 5.6%. The main cause of death was transtentorial herniation. A complete or partial recovery occurs within a few months, although 10% have persistent neurological deficits at 12 months [19]. Concern for anticoagulation treatment in CVST results from the possibility that venous infarcts to become hemorrhagic. However, the evidence from two randomized and controlled trials comparing treatment with intravenous unfractionated heparin and the low-molecular weight heparin vs placebo supports the quickly use of
anticoagulant therapy [20, 21]. It is possible that even improvement of obstruction and venular pressure could reduce the risk of further hemorrhage. Thus, after an initial period of treatment with heparin, it is advisable to continue anticoagulation with oral anticoagulation with vitamin K antagonists.

However, we have no direct specific evidence for anticoagulation in CVST, but guidelines recommend these for deep vein thrombosis and pulmonary embolism. The AHA/ASA 2011 recommends oral vitamin K antagonist during 3–6 months for provoked and 6–12 months for unprovoked in patients with CVST. In addition, the AHA/ASA 2011 recommends identifying patients with high risk to recurrent CVST and should include those with severe thrombophilia (homozygosity for prothrombin gene mutation 20210 or factor V Leiden; combined thrombophilias; deficiencies of antithrombin, protein C, or protein S; or antiphospholipid antibodies). These patients should be considered for indefinite anticoagulation therapy.

Due to the clinical particularity of our patient, we considered tinzaparin treatment for the first 6 months. The clinical follow-up of the AHA/ASA 2011 Scientific Statement advises a control imaging 3–6 months after diagnosis [7]. At this time (6 months), a new retinography already demonstrated a dramatic improvement of papilledema, but in MRV control some persistent thrombus, although fewer in number and smaller in size, was observed. Thus, we chose to extend tinzaparin for a further 6 months (12 months). After 12 months of heparin treatment, we considered discontinuing anticoagulation treatment in our patient. Mainly, because he had no associated clinical complications and presented a full resolution in thrombus images in a new MRV control at 12 months, and secondly, he was not a homozygous but a heterozygous carrier of factor V Leiden mutation. However, we thought that the thrombotic process could have injured the cerebral venous bed (factor 1 and 2 of Virchow), and this fact together with being a carrier of factor V Leiden and having a T1D with improper handling could increase the risk of a new thrombotic event. Therefore, at the end of treatment in this young patient, we were uncertain of the following: how long we should continue the treatment for and what the antithrombotic treatment should be? We made the decision to stop the treatment at 12 months. However, if you decide to continue antithrombotic treatment for an extended period, it is advisable that warfarin be chosen to target international normalized ratio of 2.0–3.0 instead of tinzaparin. Currently, these and other questions cannot be answered based on medical trial evidence and can only be answered based on expertise. Lastly, we established a specific monitoring regime for this boy: first, reinforcing education in diabetes and the implications of his self-control in achieving better blood glucose levels. Hyperglycemia is the first factor that should be controlled in a patient who carries an unmodifiable genetic prothrombotic factor. Second, this patient must continue special surveillance, including neurological controls, even if he becomes asymptomatic. At the moment, after 2 years of follow-up he remains asymptomatic without any new recurrent episodes.

Acknowledgments
Supported by grants: To JA Paniagua from Secretaría General de Calidad y Eficiencia, Junta de Andalucía (0462/2006; AI-0027/2029/2010). Grupos PAI. Junta de Andalucía. CTS651. 2009-2012.

Authorship
JAP: contributed to the study design, data collection, analysis, and interpretation and wrote the paper. RB, ACS, and FV: all contributed to analysis and interpretation.

Conflict of Interest
None declared.

References
1. Bousser, M. G., and J. M. Ferro. 2007. Cerebral venous thrombosis: an update. Lancet Neurol. 6:162–170.
2. de Veber, G., M. Andrew, C. Adams, B. Bjornson, F. Booth, D. J. Buckley, et al. 2001. Cerebral sinovenous thrombosis in children. N. Engl. J. Med. 345:417–423.
3. Heller, C., A. Heinecke, R. Junker, R. Knofler, A. Kosch, K. Kurnik, et al. 2003. Cerebral venous thrombosis in children: a multifactorial origin. Circulation 108:1362–1367.
4. Ferro, J. M., P. Canhao, J. Stam, M. G. Bousser, F. Barinagarrementeria, and I. Investigators. 2004. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35:664–670.
5. Agostoni, E. 2004. Headache in cerebral venous thrombosis. Neurol. Sci. 25(Suppl 3):S206–S210.
6. Stam, J. 2005. Thrombosis of the cerebral veins and sinuses. N. Engl. J. Med. 352:1791–1798.
7. Saposnik, G., F. Barinagarrementeria, R. D. Jr Brown, C. D. Bushnell, B. Cucchiara, M. Cushman, et al. 2011. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158–1192.
8. De Stefano, V., P. Chiusolo, K. Paciaroni, and G. Leone. 1998. Epidemiology of factor V Leiden: clinical implications. Semin. Thromb. Hemost. 24:367–379.
9. Brennan, D. C., M. B. Shannon, M. J. Koch, K. S. Polonsky, N. Desai, and J. Shapiro. 2004. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation 78:172–173.
10. Rosenbloom, A. L. 2004. Fatal cerebral infarctions in diabetic ketoacidosis in a child with previously unknown heterozygosity for factor V Leiden deficiency. J. Pediatr. 145:561–562.
11. Lee, H. S., and J. S. Hwang. 2011. Cerebral infarction associated with transient visual loss in child with diabetic ketoacidosis. Diabet. Med. 28:516–518.
12. Sasiadek, M. J., D. Sosnowska-Pacuszko, M. Zielinska, and T. Turek. 2006. Cerebral venous thrombosis as a first presentation of diabetes. Pediatr. Neurol. 35:135–138.
13. Carl, G. F., W. H. Hoffman, G. G. Passmore, E. J. Truemper, A. L. Lightsey, P. E. Cornwell, et al. 2003. Diabetic ketoacidosis promotes a prothrombotic state. Endocr. Res. 29:73–82.
14. Kruyt, N. D., G. J. Biessels, J. H. DeVries, M. J. Luitse, M. Vermeulen, G. J. Rinkel, et al. 2010. Hyperglycemia in aneurysmal subarachnoid hemorrhage: a potentially modifiable risk factor for poor outcome. J. Cereb. Blood Flow Metab. 30:1577–1587.
15. Zuurbier, S. M., S. Hiltunen, T. Tatlisumak, G. M. Peters, S. M. Silvis, E. Haapaniemi, et al. 2016. Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke 47:390–396.
16. Gulati, D., D. Strbian, and S. Sundararajan. 2014. Cerebral venous thrombosis: diagnosis and management. Stroke 45:e16–e18.
17. Coutinho, J., S. F. de Bruijn, G. Deveber, and J. Stam. 2011. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst. Rev.:CD002005.
18. 2015. Standards of medical care in diabetes-2015. Diabetes Care 38(Suppl 1):S1–S89. (http://care.diabetesjournals.org/content/38/Supplement_1).
19. Dentali, F., M. Gianni, M. A. Crowther, and W. Ageno. 2006. Natural history of cerebral vein thrombosis: a systematic review. Blood 108:1129–1134.
20. Einhaupl, K. M., A. Villringer, W. Meister, S. Mehraein, C. Garner, M. Pellkofer, et al. 1991. Heparin treatment in sinus venous thrombosis. Lancet 338:597–600.
21. de Bruijn, S. F., and J. Stam. 1999. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 30:484–488.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1. Differential diagnoses of Papilledema.
Table S2. Risk factor for several sinus thrombosis.
Figure S1. Computerized Tomography (CT): demonstrates no orbital defects.